- Financial Times•4 hours ago
Anglo-Swedish drugmaker AstraZeneca is expanding its widely watched trials for durvalumab, a potential breakthrough treatment for several forms of cancer. The drug is among a group of therapies designed ...
Review of environment and holdings
- Investor's Business Daily•5 days ago
Merck has a several-month head start on Bristol-Myers Squibb and AstraZeneca in lung cancer, Morgan Stanley says.
AZN : Summary for Astrazeneca PLC Common Stock - Yahoo Finance
AstraZeneca PLC (AZN)
NYSE - NYSE Real Time Price. Currency in USD
Add to watchlist
|Day's Range||28.38 - 28.68|
|52 Week Range||25.55 - 35.04|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||32.64|
|Dividend & Yield||0.00 (0.00%)|
|1y Target Est||N/A|